The scientific evidence of Qura | Curcumin​

Scientific evidence in the supplementation of ulcerative colitis

Curcumin in combination with mesalamine induces remission in patients with Mild-to-Moderate Ulcerative Colitis in a randomized controlled trial. Alon Lang et al. Clin Gastroenterol Hepatol. 2015

Randomized controlled trial of curcumin in combination with mesalamine to induce remission in patients with mild-to-moderate UC.

A group of researchers in Israel designed a randomized clinical trial comparing the efficacy of intestinal-targeted curcumin + mesalamine versus mesalamine alone in patients with mild-to-moderate ulcerative colitis. All patients had previously received mesalamine treatment without response.

Of the 26 patients who received curcumin+mesalamine, 53.8% achieved clinical remission at 4 weeks, while in the control group no remission was observed.

65.3% (17 pts.) showed clinical responseand endoscopic remission was observed in 38% of the patients in the group that received curcumin+mesalamine.

The study concluded that the administration of intestinal-targeted curcumin along with mesalamine was much more effective than mesalamine alone in achieving clinical and endoscopic remission in patients with active UC who do not respond to first-line pharmacological treatment.

At week 8, 72% of patients showed clinical response, 33% achieved clinical remission, and 61% achieved mucosal healing. Clinical and endoscopic indices, CRP levels, and fecal occult blood test results showed significant improvement. The study concluded that QD is effective in inducing remission in patients with moderate UC. specifically targeted to the intestine in inducing remission in patients with active UC who do not respond to pharmaceutical treatment.

The results were so promising that for the first time, curcumin was included as a complementary treatment in the therapeutic guidelines of the European Crohn’s and Colitis Organization (ECCO) in 2021, which was a major advancement for natural medicine in the field of IBD.

READ THE STUDY

Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Hanai H et al. Clin Gastroenterol Hepatol. 2006

Maintenance protocol with curcumin for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.

This randomized, multicenter, placebo-controlled clinical trial lasting more than six months more than 6 months, conducted in Japan, evaluated the role of curcumin in maintaining remission. 

89 patients (18-64 years) with UC in remission were included, and 45 of them received curcumin with sulfasalazine or mesalamine for 6 months followed by a new observational period of 6 months, with the aim of evaluating the efficacy of curcumin for its maintenance.

The trial analyzed the clinical activity index (CAI) and the endoscopic index (EI) at baseline, every 2 months, at 6 months from the start of supplementation, and subsequently, during the additional 6-month follow-up period. 

The clinical trial showed a lower relapse rate and better CAI and EI outcomes in the icurcumin group.

In the following 6 months, higher rate of relapseswas observed after stopping curcumin supplementation.

The study determined that curcumin, as a nutritional supplement, maintains remission for longer than pharmaceutical treatment alone and is therefore a safe and promising supplement for supporting and maintaining remission in patients with UC.

READ THE STUDY

Novel Bioenhanced Curcumin With Mesalamine for Induction of Clinical and Endoscopic Remission in Mild-to-Moderate Ulcerative Colitis: A Randomized Double-Blind Placebo-controlled Pilot Study. Banerjee R, et al. J Clin Gastroenterol. 2021

This study evaluated the efficacy and safety of curcumin as an adjunct to standard treatment to support the induction of remission in mild-to-moderate UC.

Of the 69 patients included in this study, 34 received curcumin along with mesalamine.

Clinical response was also significantly higher in the group that received curcumin.

The 6-month follow-up showed that 95% of patients who responded to curcumin maintained clinical remission.

These results indicate that curcumin as a supplement can help induce prolonged remission in patients with mild-to-moderate UC when administered along with mesalamine.

READ THE STUDY

Efficacy of Indigo Naturalis (QD) Therapy for Ulcerative Colitis: A Case Series. Urushikubo Jun et al. Intern Med. 2019 curcumin in the treatment of Crohn’s disease

Administration of dietary antioxidants for patients with inflammatory bowel disease: A systematic review and meta-analysis of randomized controlled clinical trials. Shahinfar H. et al. Complement Ther Med. 2021

Meta-analysis that studied the effect of curcumin in patients with IBD. They determined that curcumin significantly increased clinical and endoscopic remission in patients with IBD compared to the control group.

In addition, curcumin, when used as a complement to treatment, showed to help achieve significant improvements in clinical response and patient’s quality of life .

READ THE STUDY

CONTACT US

TO REQUEST ADDITIONAL INFORMATION

CONTACT US
0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    To find out your shipping cost , Please proceed to checkout.
    Continue Shopping

    Política de devolución

    Dispones de 14 días naturales desde la recepción del producto/s para desistir o devolver el mismo.

    No se admite la devolución ni el desistimiento, por razones de protección de la salud e higiene, cuando el envoltorio, embalaje o precinto que protege el producto, haya sido abierto. El producto deberá estar envuelto adecuadamente, con la etiqueta original, no manipulado y con todos sus componentes originales. 

    Puedes iniciar la devolución del producto contactándonos:

    Enviaremos un mensajero a recoger el producto en la dirección que nos facilites. Entrega el producto al transportista.

    El reembolso se realizará por el mismo medio de pago con el que se abonó el producto y por el importe correspondiente. Se realizará antes de que hayan transcurrido 14 días desde la fecha de recepción de la devolución en las oficinas de Adacyte.

    Los gastos derivados de la recogida del producto correrán a cargo de Adacyte. 

    Para cualquier duda, sugerencia, consulta o reclamación sobre la tienda online, puedes dirigirte al Servicio de
    atención al cliente. 

    Atención al cliente:

    • Teléfono 93 400 67 01 (en horario de lunes a jueves de 09:00h a 18:00h y viernes de 09:00h a 15:00h)
    • Correo electrónico: info@naturcyte.com 
    • Correo postal en la siguiente dirección: 

    ADACYTE THERAPEUTICS, S.L. 

    Calle Jesús Serra Santamans, 5

    08174 Sant Cugat del Vallès (Barcelona)

    España

    RECLAMACIONES

    Disponemos de hojas de reclamaciones oficiales a disposición de los consumidores y usuarios, que podrán ser presentadas en la dirección postal y correo electrónico arriba indicados. 

    Puedes solicitar la hoja de reclamaciones llamando al teléfono de atención al cliente o descargarla directamente aquí: Descargar hojas oficiales.

    El Servicio de atención al cliente de Adacyte atenderá y dará respuesta a tu reclamación a la mayor brevedad
    posible, y siempre en el plazo máximo de un mes.

    Las cookies son importantes para ti, influyen en tu experiencia de navegación, nos ayudan a proteger tu privacidad y permiten realizar las peticiones que nos solicites a través de la web. Utilizamos cookies propias y de terceros para analizar nuestros servicios y mostrarte publicidad relacionada con tus preferencias en base a un perfil elaborado con tus hábitos de navegación. Puedes Aceptar o Rechazar aquellas cookies que no sean técnicas, así o también configurar tus preferencias pulsando Configurar Cookies. Más información, consulta nuestra Política de Cookies    Configurar
    Privacidad